Paratek Financial Statements From 2010 to 2024

PRTKDelisted Stock  USD 2.18  0.00  0.00%   
Paratek Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Paratek Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Paratek Pharmaceuticals financial statements helps investors assess Paratek Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Paratek Pharmaceuticals' valuation are summarized below:
Paratek Pharmaceuticals does not presently have any trending fundamental ratios for analysis.
Check Paratek Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Paratek Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Paratek financial statements analysis is a perfect complement when working with Paratek Pharmaceuticals Valuation or Volatility modules.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Paratek Pharmaceuticals Company Return On Asset Analysis

Paratek Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Paratek Pharmaceuticals Return On Asset

    
  -0.18  
Most of Paratek Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Paratek Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Paratek Pharmaceuticals has a Return On Asset of -0.1799. This is 97.94% lower than that of the Pharmaceuticals sector and 99.24% lower than that of the Health Care industry. The return on asset for all United States stocks is 28.5% higher than that of the company.

Paratek Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Paratek Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Paratek Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Paratek Pharmaceuticals competition to find correlations between indicators driving Paratek Pharmaceuticals's intrinsic value. More Info.
Paratek Pharmaceuticals is regarded fourth in return on asset category among its peers. It is regarded second in profit margin category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Paratek Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Paratek Pharmaceuticals Financial Statements

Paratek Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Paratek Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Consideration for investing in Paratek Stock

If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Global Correlations
Find global opportunities by holding instruments from different markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Stocks Directory
Find actively traded stocks across global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity